Recherche dans les collections de brevets nationales et internationales
Une partie du contenu de cette demande n'est pas disponible pour le moment.
Si cette situation persiste, contactez-nous auObservations et contact
1. (WO2008049620) COMPOSITION SEMI-SOLIDE À LIBÉRATION CONTRÔLÉE
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

Claims

1. A semi-solid composition for the controlled release of macromolecules, comprising at least one gelatinizing agent and at least one macromolecule to be released,
wherein the macromolecule has a molecular weight of at least 1.5 kDa.

2. Composition according to claim 1, wherein the at least one gelatinizing agent is a cellulose derivative or a polyacrylate.

3. Composition according to claim 1 or claim 2, wherein the amount of the at least one gelatinizing agent in the composition is of from 0.5 to 10 percent by weight, preferably of from 0.75 to 8 percent by weight, and most preferably of from 1.0 to 7 percent by weight, based on the total weight of the composition.

4. Composition according to any one of claims 1 to 3, wherein the cellulose derivate is selected from the group consisting of alkylcelluloses, hydroxyalkylcelluloses, hydroxyalkylalkylcelluloses, carboxyalkylcelluloses and mixtures thereof.

5. Composition according to claim 4, wherein the hydroxyalkylcellulose is selected from the group consisting of hydroxy ethylcellulose, hydroxypropylcellulose and mixtures thereof.

6. Composition according to any one of claims 1 to 5, wherein the composition is a hydrogel.

7. Composition according to any one of claims 1 to 6, wherein the macromolecule to be released has a molecular weight of from 1.5 to 40 kDa, preferably of from 2.5 to 30 kDa, more preferably of from 3 to 25 kDa and most preferably of from 3.5 to
22.5 kDa.

8. Composition according to any one of claims 1 to 7, wherein the macromolecule to be released is a biopolymer.

9. Composition according to claim 8, wherein the biopolymer is a polynucleotide, a polypeptide or a polysaccharide.

10. Composition according to claim 9, wherein the length of the polynucleotide is from 5 to 50 nucleotides, preferably from 7 to 35 nucleotides, more preferably from 10 to 30 nucleotides and most preferably from 12 to 30 nucleotides.

11. Composition according to claim 9 or claim 10, wherein the polynucleotide is an antisense DNA or an antisense RNA.

12. Composition according to claim 9 or claim 10, wherein the polynucleotide is a small RNA, in particular an siRNA, an miRNA, a tnRNA or an smRNA.

13. Composition according to claim 9 or claim 10, wherein the polynucleotide is an aptamer.

14. Composition according to any one of claims 1 to 13, further comprising excipients and additives, preferably selected from the group consisting of electrolytes,
emulsifying agents, emollients, buffers, antioxidants, solubilizers, preservatives, wetting agents, permeation enhancers, transfection mediators, drug carriers and mucolytics.

15. Composition according to any one of claims 1 to 14, wherein the composition is a pharmaceutical, cosmetic or diagnostic composition.

16. Composition according to any one of claims 1 to 15 as a medicament for topical administration.

17. Use of a composition according to any one of claims 1 to 15 for preparing a
medicament for topical administration.

18. Use according to claim 17, wherein the medicament is for local administration.

19. Use according to claim 17 or claim 18, wherein the medicament is for
administration to the skin and/or the mucosa, in particular the oral, anal and genital mucosa.

20. Use according to claim 19, wherein the medicament is for administration to the cervical mucosa.

21. Use of a composition according to any one of claims 1 to 15 for the preparation of a medicament for the prevention and/or treatment of diseases of the skin and/or the mucosa, in particular of the oral, anal and genital mucosa.

22. Use according to claim 21, wherein the disease of the skin and/or the mucosa is caused by a virus.

23. Use according to claim 22, wherein the virus is a virus of the family papovaviridae or herpesviridae.

24. Use according to claim 23, wherein the virus of the family papovaviridae is a
papillomavirus and the virus of the family herpesviridae is an α-herpesvirus, in particular a herpes simplex virus or a varicella-zoster virus.

25. Application device for semi-solid compositions, containing a composition
according to any one of claims 1 to 16.